RxDoctor Payments Data

Amr Behiri, DO

Internal Medicine · Ashburn, VANPI 1154588580

Payments from drug & device makers

$15,328in general payments, 2019–2025

Across 42 payments — averaging $364.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$15K
  • Novartis$140
  • Acadia Pharmaceuticals Inc$136
  • Otsuka America Pharmaceutical, Inc.$122
  • Teva Pharmaceuticals USA, Inc.$117
  • Sunovion Pharmaceuticals Inc.$108
  • plus $126 from 2 others

What the payments were for

  • Consulting fees$8706%
  • Speaking & faculty fees$11,84077%
  • Travel & lodging$9916%
  • Food & beverage$1,60110%
  • Education$260%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,328 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$19,596
Medicare patients
295
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban3,461$1,053,305
TrulicityDulaglutide442$330,658
XareltoRivaroxaban682$205,012
XifaxanRifaximin190$199,673
NuplazidPimavanserin Tartrate60$189,722
JanuviaSitagliptin Phosphate594$176,889
JardianceEmpagliflozin402$129,911
Trelegy ElliptaFluticasone/Umeclidin/Vilanter173$107,699
Breo ElliptaFluticasone/Vilanterol228$99,111
MyrbetriqMirabegron322$94,409
Atorvastatin Calcium4,973$90,456
EntrestoSacubitril/Valsartan201$73,511
OzempicSemaglutide66$67,700
Austedo XrDeutetrabenazine21$66,907
BiktarvyBictegrav/Emtricit/Tenofov Ala14$59,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna$14,579$254,707700 claims
Acadia Pharmaceuticals IncNuplazid$136$189,72260 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$122$100,46868 claims
NovartisEntresto$140$73,511201 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$117$66,90721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Ashburn

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →